Elevess officially OK’d
Posted Wednesday, August 08, 2007
At the end of July, the much-anticipated filler Elevess, from Anika Therapeutics, received FDA approval for commercial sale. Like other hyaluronic-acid injectables, it is expected to be used by dermatologists and cosmetic surgeons for improving the appearance wrinkles and scars. However, Elevess does have two distinct differences.
First, Elevess has the highest concentration of cross-linked hyaluronic acid of any commercially available dermal filler. Because of this, experts expect longer-lasting results.
Second, Elevess has lidocaine, a local anesthetic, right in its formula—it’s the first and only available aesthetic filler to do so. Anika says this will vastly improve patient comfort and satisfaction.
Do these differences make Elevess a more appealing option for you? Let us know your thoughts and plans by leaving a comment below.
Tags: anesthetic, Anika Therapeutics, Elevess, FDA, filler, hyaluronic acid, injectable, lidocaine, scar, wrinkles